Correlates of Age at Attainment of Developmental Milestones in HIV-infected Infants Receiving Early Antiretroviral Therapy

Background: Infant HIV-1 infection is associated with impaired neurologic and motor development. Antiretroviral therapy (ART) has the potential to improve developmental outcomes but the relative contributions of pre-ART disease status, growth, treatment regimen and ART response during infancy are unknown. Methods: Kenyan ART-naive infants <5-months old initiated ART and had monthly assessment of age of full neck control, unsupported walking and monosyllabic speech during 24 months of follow-up. Pre-ART and post-ART correlates of age at milestone attainment were evaluated using t tests or multivariate linear regression. Results: Among 99 infants, pre-ART correlates of later milestone attainment included: underweight and stunted (neck control, walking and speech, all P values <0.05), missed prevention of mother-to-child transmission (P = 0.04) (neck control), previous hospitalization, World Health Organization (WHO) Stage III/IV, low CD4 count, and wasting (speech and walking, all P values <0.05), and low maternal CD4 (speech, P = 0.04). Infants initiated ART at a median of 14 days following enrollment. Infants receiving lopinavir/ritonavir-based versus nevirapine-based ART attained later speech (18.1 vs. 15.5 months, P = 0.003). Adjusting for pre-ART level, lower 6-month gain in CD4% was associated with later walking (0.18 months earlier per unit increase in CD4%; P = 0.004) and speech (0.12 months earlier per unit increase in CD4%; P = 0.05), and lower 6-month gains in weight-for-age (P = 0.009), height-for-age (P = 0.03) and weight-for-height (P = 0.02) were associated with later walking. Conclusion: In HIV-infected infants, compromised pre-ART immune and growth status, poor post-ART immune and growth responses, and use of lopinavir/ritonavir-based versus nevirapine-based ART were each associated with later milestone attainment. The long-term consequences of these delays are unknown.

[1]  Paige L. Williams,et al.  Evaluation of Risk for Late Language Emergence After In Utero Antiretroviral Drug Exposure in HIV-exposed Uninfected Infants , 2013, The Pediatric infectious disease journal.

[2]  S. Madhi,et al.  Early antiretroviral therapy improves neurodevelopmental outcomes in infants , 2012, AIDS.

[3]  B. Richardson,et al.  Survival Benefit of Early Infant Antiretroviral Therapy is Compromised When Diagnosis is Delayed , 2012, The Pediatric infectious disease journal.

[4]  M. Hughes,et al.  Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. , 2012, The New England journal of medicine.

[5]  Paige L. Williams,et al.  Language Impairment in Children Perinatally Infected With HIV Compared to Children Who Were HIV-Exposed and Uninfected , 2011, Journal of developmental and behavioral pediatrics : JDBP.

[6]  B. Chohan,et al.  Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting , 2011, BMC pediatrics.

[7]  M. Hughes,et al.  Antiretroviral treatment for children with peripartum nevirapine exposure. , 2010, The New England journal of medicine.

[8]  Sujal M. Parikh,et al.  A pilot study of the neuropsychological benefits of computerized cognitive rehabilitation in Ugandan children with HIV. , 2010, Neuropsychology.

[9]  C. Rouzioux,et al.  Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Stewart,et al.  The effect of a basic home stimulation programme on the development of young children infected with HIV , 2010, Developmental medicine and child neurology.

[11]  Paige L. Williams,et al.  Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants , 2010, Pediatrics.

[12]  C. Newton,et al.  The role of weight for age and disease stage in poor psychomotor outcome of HIV‐infected children in Kilifi, Kenya , 2009, Developmental medicine and child neurology.

[13]  A. Steenhoff,et al.  The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV , 2009, AIDS.

[14]  Paige L. Williams,et al.  Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents , 2009, AIDS.

[15]  M. Tardieu.  HIV-1 and the developing central nervous system. , 2008, Developmental medicine and child neurology.

[16]  M. Hughes,et al.  Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor–Based Highly Active Antiretroviral Therapy , 2007, Pediatrics.

[17]  L. Mofenson,et al.  A Behavioral and Cognitive Profile of Clinically Stable HIV-Infected Children , 2006, Pediatrics.

[18]  D. Drotar,et al.  Health, Neurologic, and Cognitive Status of HIV-Infected, Long-Surviving, and Antiretroviral-Naive Ugandan Children , 2006, Pediatrics.

[19]  W. Fawzi,et al.  The Timing of Mother-to-Child Transmission of Human Immunodeficiency Virus Infection and the Neurodevelopment of Children in Tanzania , 2006, The Pediatric infectious disease journal.

[20]  C. Chiriboga,et al.  Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). , 2005, The Journal of pediatrics.

[21]  O. Ramilo,et al.  Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. , 2002, The Journal of pediatrics.

[22]  C. Golden,et al.  Neuropsychological consequences of HIV in children: a review of current literature. , 2002, Clinical psychology review.

[23]  L. Magder,et al.  Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Women and Infant Transmission Study Group. , 2000, The Pediatric infectious disease journal.

[24]  M. Fowler,et al.  Early Cognitive and Motor Development Among Infants Born to Women Infected With Human Immunodeficiency Virus , 2000, Pediatrics.

[25]  L. Jagodzinski,et al.  Evaluation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay Using Primary Subtype A, C, and D Isolates from Kenya , 2000, Journal of Clinical Microbiology.

[26]  L. Meyer,et al.  HIV-1–related encephalopathy in infants compared with children and adults , 2000, Neurology.

[27]  L. Weiner,et al.  Early Language Development in Children Exposed to or Infected With Human Immunodeficiency Virus , 1998, Pediatrics.

[28]  H. Moss,et al.  Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24‐month follow‐up study , 1997, AIDS.

[29]  J. Fagan,et al.  Neurodevelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. , 1997, Pediatrics.

[30]  M. Robb,et al.  Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. , 1996, The Journal of infectious diseases.

[31]  J. Goedert,et al.  Neurologic status of human immunodeficiency virus 1-infected infants and their controls: a prospective study from birth to 2 years. Mothers and Infants Cohort Study. , 1996, Pediatrics.

[32]  W. Borkowsky,et al.  Neurodevelopment, Growth, and Viral Load in HIV-Infected Infants , 1996, Brain, Behavior, and Immunity.

[33]  C. Gay,et al.  The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: birth to 24 months. , 1995, Pediatrics.

[34]  L. Muenz,et al.  Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life. , 1994, Pediatrics.

[35]  F. Dabis,et al.  Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: a prospective cohort study in Kigali, Rwanda. , 1993, Pediatrics.

[36]  Philip Archer,et al.  The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. , 1992, Pediatrics.

[37]  J. Stockman.  Early Antiretroviral Therapy and Mortality among HIV-Infected Infants , 2010 .

[38]  Jb Obonyo,et al.  Kenya National Bureau Of Statistics (KNBS) And ICF Macro. Kenya Demographic And Health Survey 2008-09. , 2010 .

[39]  I. Grant,et al.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.

[40]  Francisco González-Scarano,et al.  The neuropathogenesis of AIDS , 2005, Nature Reviews Immunology.

[41]  C. Decarli,et al.  Brain growth and cognitive improvement in children with human immunodeficiency virus-induced encephalopathy after 6 months of continuous infusion zidovudine therapy. , 1991, Journal of acquired immune deficiency syndromes.